Medpace CEO, director and 10% owner reports MEDP stock sales

Rhea-AI Filing Summary

Medpace Holdings, Inc. (MEDP) CEO August J. Troendle, who is also a director and 10% owner, reported open-market sales of Medpace common stock. On 11/24/2025, he sold 59,025 shares at a weighted average price of $607.78 per share, and on 11/25/2025 he sold 42,392 shares at a weighted average price of $615.52 per share. After these transactions, he directly beneficially owns 774,602 shares and indirectly beneficially owns 4,733,019 shares through Medpace Investors, LLC, over which he has voting and investment control and for which he disclaims beneficial ownership beyond his economic interest.

Insights

Equity Ownership Analyst

Large insider sale by CEO/10% owner, but stake remains very substantial; signal is modestly cautious, not transformational.

The filing shows the CEO and 10% owner of Medpace Holdings, Inc. sold 59,025 shares on 11/24/2025 at a weighted average of $607.78 and 42,392 shares on 11/25/2025 at a weighted average of $615.52. These were open-market sales executed through a limit order during an open trading window. After these transactions, the reported direct holding stands at 732,210 shares of common stock.

In addition to the direct stake, the filing reports an indirect beneficial interest in 4,733,019 shares held by Medpace Investors, LLC, where the reporting person is the sole manager and controlling unit holder. The filing clarifies that he may be deemed to indirectly beneficially own these securities but disclaims beneficial ownership beyond his economic interest, which is standard language in such structures. The prices reported are weighted averages covering ranges from $593.46 to $617.165 and from $610.50 to $626.545, reflecting multiple trade executions.

This means the insider reduced direct exposure but still reports control or economic interest over several million shares, so overall alignment with shareholders remains large in absolute terms. The sales were not flagged as made under a Rule 10b5-1 trading plan, though the explanation notes they occurred via a limit order in an open window. A practical item to watch is whether similar-sized sales by this insider recur in upcoming windows after 11/26/2025, as patterns over time can change the perceived significance of a single transaction.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Troendle August J.

(Last) (First) (Middle)

C/O MEDPACE HOLDINGS, INC.

5375 MEDPACE WAY

(Street)

CINCINNATI OH 45227

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Medpace Holdings, Inc. [ MEDP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

3. Date of Earliest Transaction (Month/Day/Year)
11/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/24/2025		S(1)		59,025	D	$607.78(2)	774,602	D
Common Stock	11/25/2025		S(1)		42,392	D	$615.52(3)	732,210	D
Common Stock								4,733,019	I	By Medpace Investors, LLC(4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period.

2. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $593.46 to $617.165. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

3. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $610.50 to $626.545. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

4. The Reporting Person is the sole manager and controlling unit holder of Medpace Investors, LLC ("MPI") and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Remarks:

	/s/ Stephen P. Ewald, Attorney-in-Fact for August J. Troendle	11/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Medpace (MEDP) report in this Form 4?

The CEO, August J. Troendle, reported open-market sales of Medpace common stock on 11/24/2025 and 11/25/2025, as detailed in Table I of the filing.

How many Medpace (MEDP) shares did the CEO sell and at what prices?

On 11/24/2025, he sold 59,025 shares at a weighted average price of $607.78. On 11/25/2025, he sold 42,392 shares at a weighted average price of $615.52.

How many Medpace (MEDP) shares does the CEO own after these transactions?

Following the reported sales, he directly beneficially owns 774,602 Medpace common shares and indirectly beneficially owns 4,733,019 shares through Medpace Investors, LLC.

What is Medpace Investors, LLC in relation to Medpace (MEDP) insider holdings?

Medpace Investors, LLC holds 4,733,019 Medpace shares. August J. Troendle is its sole manager and controlling unit holder and has sole voting and investment control over those securities.

Does the CEO claim full beneficial ownership of Medpace (MEDP) shares held by Medpace Investors, LLC?

No. He may be deemed to indirectly beneficially own those shares but disclaims beneficial ownership except to the extent of his pecuniary (economic) interest.

Were the Medpace (MEDP) insider stock sales done under a specific trading instruction?

The filing states the transactions were effected pursuant to a limit order placed during an open window period, and includes a checkbox reference for Rule 10b5-1(c) trading plans.